-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45

Benzinga·08/31/2026 10:26:19
Listen to the news
Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $45.